Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.

被引：0
|
作者：
Hodi, F. Stephen
Chiarion-Sileni, Vanna
Lewis, Karl D.
Grob, Jean-Jacques
Rutkowski, Piotr
Lao, Christopher D.
Cowey, Charles Lance
Schadendorf, Dirk
Wagstaff, John
Dummer, Reinhard
Queirolo, Paola
Smylie, Michael
Butler, Marcus O.
Hill, Andrew Graham
Marquez-Rodas, Ivan
Haanen, John B. A. G.
Durani, Piyush
Wang, Peter
Wolchok, Jedd D.
Larkin, James
机构：
[1] Dana Farber Canc Inst, Boston, MA USA
[2] IOV IRCCS, Veneto Inst Oncol, Veneto, Italy
[3] Univ Colorado, Comprehens Canc Ctr, Aurora, CO USA
[4] Aix Marseille Univ, CHU Timone, Marseille, France
[5] Maria Sklodowska Curie Natl Res Inst Oncol, Warsaw, Poland
[6] Univ Michigan, Michigan Med, Rogel Canc Ctr, Ann Arbor, MI USA
[7] Texas Oncol Baylor Charles Sammons Canc Ctr, Dallas, TX USA
[8] Univ Essen & German Canc Consortium, Essen, Germany
[9] Swansea Univ, Coll Med, Swansea, W Glam, Wales
[10] Univ Spital Zurich, Zurich, Switzerland
[11] IRCCS, European Inst Oncol, IEO, Milan, Italy
[12] Cross Canc Inst, Edmonton, AB, Canada
[13] Univ Hlth Network, Div Med Oncol & Hematol, Princess Margaret Canc Ctr, Toronto, ON, Canada
[14] Tasman Oncol Res Ltd, Southport, Qld, Australia
[15] Hosp Gen Univ Gregorio Maranon, Madrid, Spain
[16] Antonivan Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands
[17] Bristol Myers Squibb, Uxbridge, Middx, England
[18] Bristol Myers Squibb, Princeton, NJ USA
[19] Mem Sloan Kettering Canc Ctr, New York, NY USA
[20] Royal Marsden Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9522
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL) who were treated beyond progression in CheckMate 066/067
    Long, Georgina V.
    Weber, Jeffrey S.
    Larkin, James
    Atkinson, Victoria
    Grob, Jean-Jacques
    Dummer, Reinhard
    Robert, Caroline
    Marquez-Rodas, Ivan
    McNeil, Catriona
    Schmidt, Henrik
    Briscoe, Karen
    Baurain, Jean-Francois
    Hodi, F. Stephen
    Wolchok, Jedd D.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [42] Regional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial (CheckMate 067)
    Grob, J-J.
    Schadendorf, D.
    Wagstaff, J.
    Marquez-Rodas, I.
    Lebbe, C.
    Ascierto, P. A.
    Hodi, F. S.
    Grossmann, K.
    Hassel, J. C.
    Walker, D.
    Bhore, R.
    Larkin, J.
    Wolchok, J. D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [43] Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
    Topalian, Suzanne L.
    Sznol, Mario
    McDermott, David F.
    Kluger, Harriet M.
    Carvajal, Richard D.
    Sharfman, William H.
    Brahmer, Julie R.
    Lawrence, Donald P.
    Atkins, Michael B.
    Powderly, John D.
    Leming, Philip D.
    Lipson, Evan J.
    Puzanov, Igor
    Smith, David C.
    Taube, Janis M.
    Wigginton, Jon M.
    Kollia, Georgia D.
    Gupta, Ashok
    Pardoll, Drew M.
    Sosman, Jeffrey A.
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (10) : 1020 - +
  • [44] Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
    Wolchok, J. D.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Rutkowski, P.
    Grob, J. -J.
    Cowey, C. L.
    Lao, C. D.
    Wagstaff, J.
    Schadendorf, D.
    Ferrucci, P. F.
    Smylie, M.
    Dummer, R.
    Hill, A.
    Hogg, D.
    Haanen, J.
    Carlino, M. S.
    Bechter, O.
    Maio, M.
    Marquez-Rodas, I.
    Guidoboni, M.
    McArthur, G.
    Lebbe, C.
    Ascierto, P. A.
    Long, G. V.
    Cebon, J.
    Sosman, J.
    Postow, M. A.
    Callahan, M. K.
    Walker, D.
    Rollin, L.
    Bhore, R.
    Hodi, F. S.
    Larkin, J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (14): : 1345 - 1356
  • [45] UPDATED RESULTS FROM A PHASE 3 TRIAL OF NIVOLUMAB (NIVO) COMBINED WITH IPILIMUMAB (IPI) IN TREATMENT-NAIVE PATIENTS WITH ADVANCED MELANOMA (MEL) (CheckMate 067)
    Wolchok, Jedd D.
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Rutkowski, Piotr
    Grob, Jean-Jacques
    Cowey, C. Lance
    Lao, Christopher D.
    Schadendorf, Dirk
    Ferrucci, Pier F.
    Smylie, Michael
    Dummer, Reinhard
    Hill, Andrew
    Haanen, John
    Maio, Michele
    McArthur, Grant
    Walker, Dana
    Jiang, Joel
    Horak, Christine
    Larkin, James
    Hodi, Stephen
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 127 - 128
  • [46] First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data (vol 42, 33, 2024)
    Long, Georgina V.
    Lipson, Evan J.
    Hodi, F. Stephen
    Ascierto, Paolo A.
    Larkin, James
    Lao, Christopher
    Grob, Jean-Jacques
    Ejzykowicz, Flavia
    Moshyk, Andriy
    Garcia-Horton, Viviana
    Zhou, Zheng-Yi
    Xin, Yiqiao
    Palaia, Jennell
    McDonald, Laura
    Keidel, Sarah
    Salvatore, Anthony
    Patel, Divya
    Sakkal, Leon A.
    Tawbi, Hussein
    Schadendorf, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (11) : 1398 - 1398
  • [47] Comparative Analysis of Intracranial Response Assessment Criteria in Patients With Melanoma Brain Metastases Treated With Combination Nivolumab plus Ipilimumab in CheckMate 204
    Huang, Raymond Y.
    Youssef, Gilbert
    Nelson, Thomas
    Wen, Patrick Y.
    Forsyth, Peter
    Hodi, F. Stephen
    Margolin, Kim
    Algazi, Alain P.
    Hamid, Omid
    Lao, Christopher D.
    Ernstoff, Marc S.
    Moschos, Stergios J.
    Atkins, Michael B.
    Postow, Michael A.
    Reardon, David A.
    Grootendorst, Diederik J.
    Leung, David
    Askelson, Margarita
    Ritchings, Corey
    Tawbi, Hussein A.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (10)
  • [48] The Ipilimumab Lesson in Melanoma: Achieving Long-Term Survival
    Delyon, Julie
    Maio, Michele
    Lebbe, Celeste
    SEMINARS IN ONCOLOGY, 2015, 42 (03) : 387 - 401
  • [49] Real-world outcomes in advanced melanoma patients treated with first-line nivolumab plus ipilimumab
    Kozak, Katarzyna
    Teterycz, Pawel
    Galus, Lukasz
    Mackiewicz, Jacek
    Galwas-Kliber, Katarzyna
    Kaminska-Winciorek, Grazyna
    Brandys, Piotr
    Cybulska-Stopa, Bozena
    Kempa-Kaminska, Natasza
    Zietek, Marcin
    Zubrowska, Justyna
    Dziura, Robert
    Dembinski, Mateusz
    Bereza, Michal
    Czarnecka, Anna Malgorzata
    Rutkowski, Piotr
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] COST-EFFECTIVENESS OF NIVOLUMAB PLUS IPILIMUMAB IN ADVANCED MELANOMA
    Tibet, B.
    VALUE IN HEALTH, 2018, 21 : S45 - S45
12345